AROMUC 5AC
Alternative Names: ARO-MUC5ACLatest Information Update: 20 Jun 2023
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antiasthmatics; Small interfering RNA
- Mechanism of Action Mucin 5AC expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Asthma
- Phase I Obstructive airway disorders
Most Recent Events
- 20 Jun 2023 Phase-I clinical trials in Obstructive airway disorders (Inhalation) (Arrowhead Pharma pipeline, June 2023)
- 07 Jun 2023 Phase-I/II clinical trials in Asthma (Treatment-experienced) in Spain (Inhalation) (EudraCT2022-003467-21)
- 30 Jan 2023 Phase-I/II clinical trials in Asthma (Treatment-experienced) in Australia (Inhalation) (NCT05292950)